TY  - JOUR
A1  - Altieri, Barbara
A1  - La Salvia, Anna
A1  - Modica, Roberta
A1  - Marciello, Francesca
A1  - Mercier, Olaf
A1  - Filosso, Pier Luigi
A1  - de Latour, Bertrand Richard
A1  - Giuffrida, Dario
A1  - Campione, Severo
A1  - Guggino, Gianluca
A1  - Fadel, Elie
A1  - Papotti, Mauro
A1  - Colao, Annamaria
A1  - Scoazec, Jean-Yves
A1  - Baudin, Eric
A1  - Faggiano, Antongiulio
T1  - Recurrence-free survival in early and locally advanced large cell neuroendocrine carcinoma of the lung after complete tumor resection
JF  - Journal of Personalized Medicine
N2  - Background: Large Cell Neuroendocrine Carcinoma (LCNEC) is a rare subtype of lung cancer with poor clinical outcomes. Data on recurrence-free survival (RFS) in early and locally advanced pure LCNEC after complete resection (R0) are lacking. This study aims to evaluate clinical outcomes in this subgroup of patients and to identify potential prognostic markers. Methods: Retrospective multicenter study including patients with pure LCNEC stage I-III and R0 resection. Clinicopathological characteristics, RFS, and disease-specific survival (DSS) were evaluated. Univariate and multivariate analyses were performed. Results: 39 patients (M:F = 26:13), with a median age of 64 years (44–83), were included. Lobectomy (69.2%), bilobectomy (5.1%), pneumonectomy (18%), and wedge resection (7.7%) were performed mostly associated with lymphadenectomy. Adjuvant therapy included platinum-based chemotherapy and/or radiotherapy in 58.9% of cases. After a median follow-up of 44 (4–169) months, the median RFS was 39 months with 1-, 2- and 5-year RFS rates of 60.0%, 54.6%, and 44.9%, respectively. Median DSS was 72 months with a 1-, 2- and 5-year rate of 86.8, 75.9, and 57.4%, respectively. At multivariate analysis, age (cut-off 65 years old) and pN status were independent prognostic factors for both RFS (HR = 4.19, 95%CI = 1.46–12.07, p = 0.008 and HR = 13.56, 95%CI 2.45–74.89, p = 0.003, respectively) and DSS (HR = 9.30, 95%CI 2.23–38.83, p = 0.002 and HR = 11.88, 95%CI 2.28–61.84, p = 0.003, respectively). Conclusion: After R0 resection of LCNEC, half of the patients recurred mostly within the first two years of follow-up. Age and lymph node metastasis could help to stratify patients for adjuvant therapy.
KW  - neuroendocrine tumor
KW  - LCNEC
KW  - pulmonary cancer
KW  - prognostic marker
KW  - prognosis
KW  - survival
KW  - lymph nodes
KW  - age
KW  - surgery
KW  - adjuvant therapy
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-304000
SN  - 2075-4426
VL  - 13
IS  - 2
ER  - 
TY  - JOUR
A1  - Altieri, Barbara
A1  - Di Dato, Carla
A1  - Modica, Roberta
A1  - Bottiglieri, Filomena
A1  - Di Sarno, Antonella
A1  - Pittaway, James F.H.
A1  - Martini, Chiara
A1  - Faggiano, Antongiulio
A1  - Colao, Annamaria
T1  - Bone metabolism and vitamin D implication in gastroenteropancreatic neuroendocrine tumors
JF  - Nutrients
N2  - Patients affected by gastroenteropancreatic–neuroendocrine tumors (GEP–NETs) have an increased risk of developing osteopenia and osteoporosis, as several factors impact on bone metabolism in these patients. In fact, besides the direct effect of bone metastasis, bone health can be affected by hormone hypersecretion (including serotonin, cortisol, and parathyroid hormone-related protein), specific microRNAs, nutritional status (which in turn could be affected by medical and surgical treatments), and vitamin D deficiency. In patients with multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome associated with NET occurrence, bone damage may carry other consequences. Osteoporosis may negatively impact on the quality of life of these patients and can increment the cost of medical care since these patients usually live with their disease for a long time. However, recommendations suggesting screening to assess bone health in GEP–NET patients are missing. The aim of this review is to critically analyze evidence on the mechanisms that could have a potential impact on bone health in patients affected by GEP–NET, focusing on vitamin D and its role in GEP–NET, as well as on factors associated with MEN1 that could have an impact on bone homeostasis.
KW  - bone
KW  - vitamin D
KW  - neuroendocrine tumor
KW  - osteoporosis
KW  - mineral bone density
KW  - cortisol
KW  - serotonin
KW  - miRNA
KW  - MEN1
KW  - therapy
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-203823
SN  - 2072-6643
VL  - 12
IS  - 4
ER  -